Carfilzomib治疗复发/难治多发性骨髓瘤的临床进展  

Advances of carfilzomib in treatment of relapsed and refractory multiple myeloma

作　　者：邹彬镔[1,2] 石庆之[1] 

机构地区：[1]南昌大学第二附属医院血液科,江西南昌330006 [2]南昌大学研究生院医学部,江西南昌330006

出　　处：《基础医学与临床》2014年第3期418-421,共4页Basic and Clinical Medicine

摘　　要：Carfilzomib为2代蛋白酶体抑制剂,近期已用于复发/难治多发性骨髓瘤(RRMM)的治疗。该药对硼替佐米耐药和未接受过硼替佐米治疗的患者都有较好疗效,且不良反应可耐受。与1代蛋白酶体抑制剂硼替佐米比较,Carfilzomib引起的外周神经病变少见。Carfilzomib is a second-generation selective proteasome inhibitor which has been recently used for re lapse or refractory multiple myeloma（RRMM）. bortezomib-naive patients, with a tolerable side ceiving carfilzomib compared to bortezomib. It has been shown to be beneficial in both bortezomib-resistant and effect profile. Peripheral neuropathy is less common in patients receiving carfilzomib compared to bortezomib.

关 键 词：Carfilzomib 蛋白酶体抑制剂 多发性骨髓瘤 复发 难治 抗骨髓瘤 

分 类 号：R733.3[医药卫生—肿瘤]